Smith & Nephew plc (SNN)
- Previous Close
28.85 - Open
25.46 - Bid --
- Ask 25.06 x 900
- Day's Range
24.83 - 25.62 - 52 Week Range
23.65 - 31.72 - Volume
2,504,494 - Avg. Volume
676,732 - Market Cap (intraday)
12.459B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
35.84 - EPS (TTM)
0.70 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield 0.75 (2.99%)
- Ex-Dividend Date Oct 4, 2024
- 1y Target Est
36.17
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
www.smith-nephew.comRecent News: SNN
View More
Performance Overview: SNN
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNN
View MoreValuation Measures
Market Cap
10.86B
Enterprise Value
13.95B
Trailing P/E
35.95
Forward P/E
10.20
PEG Ratio (5yr expected)
0.38
Price/Sales (ttm)
1.94
Price/Book (mrq)
2.10
Enterprise Value/Revenue
2.47
Enterprise Value/EBITDA
14.04
Financial Highlights
Profitability and Income Statement
Profit Margin
5.41%
Return on Assets (ttm)
4.51%
Return on Equity (ttm)
5.84%
Revenue (ttm)
5.64B
Net Income Avi to Common (ttm)
305M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
568M
Total Debt/Equity (mrq)
70.22%
Levered Free Cash Flow (ttm)
247.88M
Research Analysis: SNN
View MoreCompany Insights: SNN
SNN does not have Company Insights
Research Reports: SNN
View MoreSmith & Nephew Earnings: Quarterly Sales Suggest China Weakness Into 2025
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetSmith & Nephew Sees Challenges in China Market
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetSmith & Nephew: Turnaround Is Taking Hold, and New Products Should Support Moat
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetSmith & Nephew: Management’s Turnaround Plan Shows Green Shoots, but the US Still Trails
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target